公开(公告)号：US20210061813A1

公开(公告)日：2021-03-04

申请号：US16440442

申请日：2019-06-13

申请人： AbbVie Inc.

发明人： Neil WISHART ,  Maria A. ARGIRIADI ,  David J. CALDERWOOD ,  Anna M. ERICSSON ,  Bryan A. FIAMENGO ,  Kristine E. FRANK ,  Michael M. FRIEDMAN ,  Dawn M. GEORGE ,  Eric R. GOEDKEN ,  Nathan S. JOSEPHSOHN ,  Biqin C. LI ,  Michael J. MORYTKO ,  Kent D. STEWART ,  Jeffrey W. VOSS ,  Grier A. WALLACE ,  Lu WANG ,  Kevin R. WOLLER

IPC分类号： C07D487/14 ,  A61K45/06 ,  A61K31/4985 ,  A61K31/437 ,  C07D471/14 ,  C07D498/14 ,  C07D513/14

摘要： The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

公开(公告)号：US20140099313A1

公开(公告)日：2014-04-10

申请号：US14101145

申请日：2013-12-09

申请人： AbbVie Inc.

发明人： Chengbin WU ,  Richard W. DIXON ,  Jonathan P. BELK ,  Maria A. ARGIRIADI ,  Hua YING ,  Carolyn A. CUFF ,  Terry L. MELIM ,  Shankar KUMAR ,  Paul R. HINTON ,  Yan CHEN

IPC分类号： C07K16/24 ,  A61K45/06 ,  A61K39/395

CPC分类号： A61K45/06 ,  A61K38/00 ,  A61K39/3955 ,  C07K14/47 ,  C07K16/244 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/385 ,  Y02A50/401 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/463 ,  Y02A50/473 ,  Y02A50/478 ,  Y02A50/481

摘要： The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

摘要翻译： 本发明包括IL-13结合蛋白。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-13具有高亲和力，并在体外和体内中和hIL-13活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-13和抑制hIL-13活性，例如在患有hIL-13活性有害的病症的人类受试者中。

公开(公告)号：US20230082167A1

公开(公告)日：2023-03-16

申请号：US17575731

申请日：2022-01-14

申请人： AbbVie Inc.

发明人： Neil WISHART ,  Maria A. ARGIRIADI ,  David J. CALDERWOOD ,  Anna M. Ericsson ,  Bryan A. FIAMENGO ,  Kristine E. FRANK ,  Michael M. FRIEDMAN ,  Dawn M. GEORGE ,  Eric R. GOEDKEN ,  Nathan S. JOSEPHSOHN ,  Biqin C. LI ,  Michael J. MORYTKO ,  Kent D. STEWART ,  Jeffrey W. VOSS ,  Grier A. WALLACE ,  Lu WANG ,  Kevin R. WOLLER

IPC分类号： C07D487/14 ,  C07D498/14 ,  C07D513/14

摘要： The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

公开(公告)号：US20170340737A1

公开(公告)日：2017-11-30

申请号：US15457264

申请日：2017-03-13

申请人： AbbVie Inc.

发明人： Chengbin WU ,  Richard W. DIXON ,  Jonathan P. BELK ,  Hua YING ,  Maria A. ARGIRIADI ,  Carolyn A. CUFF ,  Paul R. HINTON ,  Shankar KUMAR ,  Terry L. MELIM ,  Yan CHEN

IPC分类号： A61K45/06 ,  C07K16/24 ,  A61K39/395 ,  C07K14/47 ,  A61K38/00

CPC分类号： A61K45/06 ,  A61K38/00 ,  A61K39/3955 ,  C07K14/47 ,  C07K16/244 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/385 ,  Y02A50/401 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/463 ,  Y02A50/473 ,  Y02A50/478 ,  Y02A50/481

摘要： The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.